SEOM clinical guideline for treatment of kidney cancer (2017)
-
E. Gallardo [6] ; M. J. Méndez-Vidal [7] ; J. L. Pérez-Gracia [1] ; J. M. Sepúlveda-Sánchez [2] ; M. Campayo [8] ; I. Chirivella-González [9] ; X. García-del-Muro [3] ; A. González-del-Alba [4] ; E. Grande [5] ; C. Suárez [10]
-
[1] Universidad de Navarra
Universidad de Navarra
Pamplona, España
-
[2] Hospital Universitario 12 de Octubre
Hospital Universitario 12 de Octubre
Madrid, España
-
[3] Institute Catalá Oncología
Institute Catalá Oncología
Barcelona, España
-
[4] Hospital Universitario Son Espases
Hospital Universitario Son Espases
Palma de Mallorca, España
-
[5] Hospital Ramón y Cajal
Hospital Ramón y Cajal
Madrid, España
-
[6] Parc Taulí Hospital Universitari, España
-
[7] Maimonides Institute of Biomedical Research, España
-
[8] Hospital Universitari Mutua Terrassa, España
-
[9] Hospital Clínico Valencia, España
-
[10] Hospital Universitario Vall d’Hebron, España
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 20, Nº. 1 (January 2018), 2018, págs. 47-56
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be considered the standard for second and further lines of therapy. Response evaluation for present therapies is a challenge.
